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INTRODUCTION 
 
 
 
 
 
 
 
INTRODUCTION 
The incidence of jaundice in India varies from 0.4 to 0.9/1000 deliveries. Jaundice 
in pregnancy carries a grave prognosis for both the mother and the fetus , and is 
responsible for 10% of maternal deaths. Liver disease in pregnancy is an important 
medical disorder seen more often in developing countries than in developed ones. 
The present study analyzes the causes and the fetomaternal outcome in pregnancies 
affected with jaundice.                         
  
Abnormal liver test results are obtained in 3% to 5% of pregnancies because of 
many potential causes and the clinical outcomes ranges from self-limiting to 
rapidly fatal. 
The main causes for abnormal liver tests in pregnant patientsare: 
(1) Pregnancy-related liver disease. These are the common reasons for abnormal 
liver function tests in pregnancy. Five liver diseases unique to pregnancy 
includes the following - 
(i) Hyperemesis gravidarum (HG) 
(ii)  Intrahepatic cholestasis of pregnancy (ICP)  
(iii) Preeclampsia 
(iv) Hemolysis, elevated liver enzymes, and low 
platelets (HELLP)  
(v) Acute fatty liver of pregnancy (AFLP). 
(2) Newly acquired liver diseases like acute viral hepatitis, drug induced liver 
injury, or gallstones 
(3) Preexisting chronic liver disease such as cholestatic liver disease, 
autoimmune hepatitis, Wilson disease, and chronic viral hepatitis. 
(4) physiologic changes in pregnancy  - Abnormal liver function test due to 
physiological changes in  pregnancy without liver dysfunction have a unique 
pattern. 
 
The common maternal complications  encountered are Encephalopathy, 
Disseminated intravascular coagulation , Renal failure , Shock, Postpartum 
hemorrhage , Pyrexia and also Death. 
Elevated level of serum bilirubin causes vasoconstrictive effect on the 
placental vessels and cardiotoxic effect resulting in fetal asphyxia and intrauterine 
death . Also elevated bilirubin produce cellular effect which stimulates uterine 
contractility and sensitizes  myometrium to oxytocin resulting in preterm labour. 
 
 
 
 High maternal mortality and morbidity in our country are due to many 
factors like Poor hygiene , inadequate sanitation , malnutrition, prevalence of 
anemia,  delay in seeking medical advice, lack of awareness ,and delay in referral 
to the higher centers. Many patients are brought in moribund condition to the 
hospital at admission itself and hence they do not respond to treatment.  
The prevalence of viral hepatitis in pregnancy can be reduced by creating 
public awareness, proper sanitation facilities, safe drinking water, immunization 
against viral hepatitis , improved antenatal care for early detection and well 
equipped hospitals for intensive care . Thereby, mortality and morbidity of 
jaundice complicating pregnancy can be decreased. 
The aim of this study is to identify the various etiologies and distribution of jaundice 
with reference to age , parity and trimesters  and also to determine the fetomaternal 
outcome among the pregnant women affected by jaundice treated at                                            
Government Rajaji Hospital , Madurai. 
 
 
 
 
 
 
HISTORY 
Jaundice was once called the "morbus regius"  with a belief that only the 
touch of a king could cure it. Jaune in French means yellow from which the word 
jaundice was derived. 
Before 400 B.C Hippocrates has written about the yellow discoloration in 
association with fever. Hippocratic physicians have treated liver disease and night 
blindness with raw ox liver soaked in honey. 
 In 1724 Cotton Mather has stated that `` Morbus Regius, or  The Royal 
Disease; because it brings with it the Colour of  Gold unto them that have it.`` 
In 1864 , Stadeler coined the term bilirubin. 
From 1862 Friedrich Theodor  Frerichs is called as the father of modern 
liver pathology following his publication  “ Klinik der  Leberkrankheiten ” in the 
year 1858. 
 
                            (Friedrich Theodor  Frerichs) 
 ANATOMY OF LIVER 
Liver is the largest exocrine gland in the body weighing about 1.5 kg in an average 
adult weighing about 70 kg. This is located in the right hypochondrium and a part of  
epigastric region.  
Liver is attached to the anterior abdominal wall and the diaphragm by four distinctive 
ligaments:  
(1)Coronary ligament which connects the posterior surface of the right  hepatic lobe to 
the diaphragm with a superior and an inferior layer between that lies in the bare area of 
the liver; 
(2)Right triangular ligament which is formed by fusion of the superior and inferior 
layers of the coronary ligament;  
(3)Left triangular ligament which connects the posterior surface of the left lobe of the 
liver to the diaphragm  
(4)Falciform ligament which extends from the diaphragm and anterior wall above the 
level of the umbilicus to the surface of the liver, where it divides the left hepatic lobe 
into the left lateral and left medial segments 
  
Liver segment is divided into eight segments . COUINAUD coined a system for liver 
segmental nomenclature  (8 segments). Liver is divided into segments by a longitudinal 
planes drawn through each hepatic vein to the vena cava and a transverse plane at the 
level of the main portal bifurcation .Cantlie’s line marks the course of the middle 
hepatic vein  
 
 
 
BLOOD SUPPLY 
The two sources that supply blood to the liver  are Hepatic artery and portal vein. 
Hepatic artery is a branch from celiac trunk of aorta . Portal vein is formed by the 
confluence of the superior mesenteric vein and the splenic vein at the level of the 
second lumbar vertebra behind the head of pancreas . It supplies about  75% of the total 
liver blood supply by volume. 
Blood exits the liver via the central vein accounting for  25% of cardiac output. 
Blood flow into the liver is controlled by number of factors like Muscular sphincters ,  
autonomic nervous system, circulating hormones, bile salts, and metabolites . 
 
VENOUS DRAINAGE 
Majority of the venous drainage of the liver occurs through three hepatic veins . 
Right hepatic vein drains the segments 6,7,8 and enters directly into the vena cava.   
Middle hepatic vein drains segments 5 and  inferior part of segment 4 . Left hepatic 
vein  drains the segments 2,3 and superior part of 4.  
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PORTAL TRIAD 
Branches of portal vein, hepatic artery and the biliary ducts bound together in the  
perivascular fibrous capsule to form portal triad.  Hepatocytes are arranged in plates 
joined with tight junctions  and the  apical membrane forms the biliary caniculi  
Hepatocytes are segregated from the blood-filled sinusoids by fenestrated 
endothelial cells without a basement membrane, and by a loose connective tissue layer 
known as the space of Disse. 
HEPATIC STELLATE CELLS 
These are Star shaped cells that reside in the space of Disse. It helps to Store 
lipids particularly vitamin A. 
Inflammatory cytokines cause activation, which involves the loss of stores of 
vitamin A and a dramatic upregulation in the production of extracellular matrix 
materials, such as collagen. When collagen is deposited in the space of Disse it  impairs 
hepatic function.  
KUPFFER CELLS 
Kupffer cells belongs to macrophage lineage. The sinusoids are lined by kupffer 
cells which clear the cellular debris and other particulate material and to some extent 
bacteria that enters the portal triad. 
They express cell-surface receptors for altered proteins. Fc immunoglobulin 
receptors used to internalize foreign proteins or microorganisms that have been coated 
with host antibodies.  
BILIARY SYSTEM 
Gallbladder is a biliary reservoir that lies against the inferior surface of segments 
IV and V of the liver, usually making an impression against it. A peritoneal layer covers 
most of the gallbladder except for the portion adherent to the liver. The size is variable, 
but usually about 10 cm long and 3 to 5 cm wide. Gallbladder is composed of a fundus, 
body, infundibulum, and neck . Ultimately empties into the cystic duct  
 
BIOCHEMICAL FUNCTIONS OF LIVER 
1. storage of substances like protein , glycogen , vitamins  and folic acid.. 
2. Synthesis of plasma proteins , glycogen , phospholipids , bile acids and heparin . 
3. Secretion of bile acids and bile pigments into the bile. 
4. Metabolism of carbhohydrate , protein and fat. 
5. Excretion of heavy metals , hormones, cholesterol and bile pigments. 
6. Detoxification of ingested drugs. 
7. In fetal life the liver produces RBC and WBC. 
8. Kupfer cells acts as body defence. 
9. Thyroxine is converted into triiodothyronin.and also participates in the activation 
of vitamin D. 
10. Converts toxic substances into nontoxic substances e.g., benzoic acid is 
converted into hippuric acid by conjugation with glycine. Ammonia is converted 
to urea. 
PRODUCTION AND METABOLISM OF BILIRUBIN: 
SOURCE OF BILIRUBIN: 
Mainly 80% is from senescent RBC and about 15 -20 % from ineffective erythropoiesis  
Metabolism of haem containing protein can be divide into three phases:  
(i) Hepatic uptake 
(ii) Conjugation 
(iii) Excretion into bile (rate limiting step) 
UPTAKE:  
                  Unconjugated bilirubin bound to albumin enters liver and the complex  
 dissociates. Non-polar bilirubin enters the hepatocyte by diffusion or  
transport across plasma membrane. It binds to cytoplasmic anion binding protein   
ligandin glutathione-s-transferase and prevents efflux of bilirubin back into plasma. 
CONJUGATION: 
 Unconjugated bilirubin is water insoluble. Hence gets conjugated  
to glucuronic acid forming bilirubin glucoranide , which is water-soluble. 
Conjugation occurs in endoplasmic reticulam. Catalysed by glucuronyl transferase in  
two step reaction. 
EXCRETION: 
• Conjugated  bilirubin is water soluble and is secreted by the hepatocytes into the 
biliary canaliculi . It is converted to stercobilinogen by bacteria in the gut am 
Oxidized to stercobilin which is colored. Excreted in feces. Some stercobilin 
may be re-adsorbed by the gut and re-excreted by either the liver or kidney  
 
 
 
 
 
  
 
 
Causes of  Unconjugated hyperbilirubinaemia: 
1) Increased bilirubin formation  e.g., Haemolysis ,  Ineffective  erythropoiesis ,  
Blood transfusion and  Haematoma. 
2) Decreased bilirubin uptake by hepatocyte  e.g., Drugs like Rifampicin , 
Gilbert’s syndrome 
3) Deficit in conjugation - Gilbert’s syndrome ,  Crigler Najjar ,  Drugs 
 
 
Causes of  Unconjugated hyperbilirubinaemia: 
1) Dubin-Johnson syndrome, Rotor’s syndrome 
2) Hepatocellular dysfunction 
3) Hepatic disorder with prominent cholestasis 
4) Biliary duct obstruction 
  
PREHEPATIC JAUNDICE 
Prehepatic jaundice results from excessive RBC lysis as in haemolytic anaemia . 
Unconjugated bilirubin level is increased. 
 
HEPATIC JAUNDICE 
As a result of liver dysfunction there is impairment of uptake , conjugation and 
secretion of bilirubin , hence both direct and indirect bilirubin level increases. 
 
 
POSTHEPATIC JAUNDICE 
When there is obstruction to biliary tree , the  conjugated biliribin level gets elevated. 
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PHYSIOLOGIC CHANGES IN LIVER FUNCTION TESTS DURING 
PREGNANCY 
 
 
 
Liver Test Results 
 
 Physiologic Changes Compared With 
Normal Range 
 
 
 
 
Increased 
 
 
Alkaline phosphatase , fibrinogen, 
fetoprotein, white 
blood cell, ceruloplasmin, cholesterol , 
alpha or/and 
beta globulins, triglycerides 
 
 
Unchanged 
 
Aminotransferases, prothrombin time 
 
 
Decreased 
 
Bilirubin, g-globulin, hemoglobin  
DISEASE PRESENTATION AND THE TIMING OF ONSET DURING 
PREGNANCY 
 
Disease 
Categories 
 
First Trimester 
 
Second 
Trimester 
 
Third 
Trimester 
 
Preexisting Liver 
Diseases 
 
Chronic hepatitis B or C, autoimmune 
hepatitis, primary sclerosing cholangitis, 
Wilson disease, primary biliary cirrhosis, 
cirrhosis 
Newly Acquired 
Liver 
Diseases 
 
Viral hepatitis, gallstones, drugs, sepsis, 
Budd-Chiari syndrome 
Diseases Related 
to Pregnancy 
Hyperemesis 
gravidorum 
Intrahepatic 
cholestasis 
ICP, AFLP , 
preeclampsia, 
HELLP   
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AIMS AND OBJECTIVES OF OUR STUDY :   
                                           -     To analyze the maternal outcome in terms of mode of 
  termination of pregnancy, maternal complications and 
  mortality of jaundice complicating pregnancy. 
- To identify the relation of maternal morbidity and 
mortality in relation to admission serum bilirubin 
level. 
- To assess fetal outcome by perinatal mortality and 
morbidity.  
- To identify the various etiologies and distribution of 
jaundice with reference to age , parity and trimesters. 
 
Inclusion criteria :                pregnant women affected by jaundice treated in   
                                              Government Rajaji Hospital, Madurai. 
 
Exclusion criteria :               jaundice in pregnant women occurring due to septic  
                                             etiology 
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REVIEW OF LITERATURE 
 
LIVER DISEASES RELATED TO PREGNANCY 
HYPEREMESIS GRAVIDARUM 
HG is defined as intractable nausea and vomiting during the first trimester of 
pregnancy. Most severe illness in the spectrum of vomiting in pregnancy.1 In 0.3% 
of pregnancies it may lead to dehydration and electrolyte imbalance. But usually 
resolves by 16 to 18 weeks. In up to 10% of women, symptoms continues 
throughout  pregnancy and resolve only with delivery of the fetus.2,3 
The mechanism for  Hyperemesis remains unclear. Proposed mechanisms include 
hormonal imbalance with elevated levels of human chorionic gonadotropin (HCG) 
and estrogen and decreased levels of prolactin, along with overactivity of the 
hypothalamic-pituitary-adrenal axis.4,5 High level of HCG stimulates the thyroid 
gland and upregulate the secretary processes of the upper gastrointestinal tract.4 
High levels of TNF a, IgG, IgM, C3, C4, natural killer cells, and extrathymic            
T cells observed in these women suggest that cytokine, T cell–mediated immune 
reactivation, immunoglobulin and complement play an important role in 
Hyperemesis.6,7 
Risk factors  includes – 
a. Molar pregnancy 
b. Multiple pregnancies 
c. Preexisting diabetes or hyperthyroidism 
d. Psychiatric disorders 
 
Hyperemesis is a clinical diagnosis and based on exclusion of other underlying or 
newly acquired liver diseases.2 
An abnormal LFT is seen in up to 50% of cases.8 Transaminases are usually 
2 to10 fold  elevated. Rarely can be up to 20 times the normal with mild jaundice. 
 HG resolves in most patients with the replacement of electrolytes and glucose, 
rehydration, and nutritional support. 
Parenteral hydrocortisone may lead to rapid resolution in severe cases, with slow 
improvement. Serious complications like malnutrition, esophageal tear ,9,10 
hyperthyroidism,3 or even Wernicke encephalopathy caused by vitamin B12 
deficiency can occur rarely.11 
 
INTRAHEPATIC CHOLESTASIS OF PREGNANCY 
Elevated bile acid (BA) levels during the late second or third trimester of 
pregnancy, with resolution after delivery associated with pruritus.  
Risk factors for ICP are advancing maternal age, twin pregnancies, multiparity and 
oral contraceptive use. Prevalence is 1 in 1000 to 1 in 10000. 
Cause of ICP is multifactorial, involving genetic, hormonal, and exogenous 
factors. Sex hormones can cause cholestatic effects through inhibition of the 
hepatocellular bile salt export pump (Bsep).12 Also , pregnancy is associated with 
an abnormal metabolic response with impaired sulfation. The hepatic transport 
systems for biliary excretion are affected and saturated by the large amount of 
sulfated progesterone metabolites.13,14 Genetic studies suggests that at least 10 
different multidrug resistance–associated protein (MDR) 3 mutations have been 
identified in progressive familial intrahepatic cholestasis.15 
 
Pruritus usually starts during weeks 25 to 32 of pregnancy and resolves after 
delivery , excoriations caused by scratching are often noted on physical 
examination. Serum abnormalities detected 4 weeks after the onset of pruritus.16 
Early and specific abnormality is the elevation of serum total bilirubin acid level, 
and it is usually less than 5 mg/dL. Fetal morbidity and mortality are correlated 
with maternal BA levels. 
 
Jaundice occurs in 10%to25%of patients and some may have diarrhea. Clinical 
improvement in ICP with the administration of cholestyramine,17 dexamethasone,18 
and S-adenosyl-L-methionine. 
Antihistamines,benzodiazepines, phenobarbital, and epomediol have no benefit. 19. 
UDCA is the treatment of choice for ICP. 
 Close monitoring and early delivery after confirming fetal lung maturity may be 
the best way to prevent sudden antenatal death. Glantz and colleagues 24 have 
suggested using maternal BA levels of 40 mmol/L as a threshold for early delivery. 
 
 
 
 
 
 
 
 
 
 
 
 
HELLP SYNDROME 
HELLP syndrome is a multisystem disorder characterized by hemolysis, elevated 
levels of liver enzymes, and low platelet counts with or without preeclampsia. 
 The prevalence is estimated to be 0.6% of deliveries.21 Risk factors are advanced 
maternal age, Whites and multiparity. It occurs in the third trimester in two-thirds 
of the Patients. Microangiopathic hemolytic anemia is associated with vascular 
endothelial injury, fibrin deposition in blood vessels, and platelet activation with 
platelet consumption. It is the hallmark of the syndrome but is not specific to this 
entity. 
                            Periportal or focal parenchymal necrosis with hyaline deposition 
of fibrin material in the sinusoids is the characteristic histopathological finding.22,23 
Clinical symptoms includes epigastric or right upper quadrant pain, malaise, 
headache, nausea, and vomiting.  
                             On physical examination, hypertension,generalized edema, and 
weight gain are common signs. 
Three laboratory criteria:  
 Thrombocytopenia 
 Elevated aminotransferase levels 
 Hemolysis. Several different classifications have 
been proposed. 
Platelet count less than 100,000/mm3, aspartate aminotransferase levels greater 
than 70 U/L, and L-lactate dehydrogenase (LDH) levels greater than or equal to 
600 U/L are helpful to make the diagnosis. The Mississippi classification is based 
on the degree of thrombocytopenia and the elevation of transaminase and LDH 
levels. Mississippi classification is for assessing the severity of the pathologic 
process. Frequent complications are disseminated intravascular coagulopathy 
(30%), abruptio placentae (16%), acute kidney injury (7.7%), aspiration 
pneumonia (7%), pulmonary edema (6%), acute respiratory distress syndrome, 
cardiopulmonary arrest (4%), cerebral hemorrhage (1.2%), and retinal detachment 
(0.9%). Rarely, severe ascites, subcapsular hematoma, hepatic failure, and hepatic 
rupture can occur (0.015%).24,25 
 Proteinuria is not required to make the diagnosis. 
Computed tomography (CT) may show subcapsular hematomas, intraparenchymal 
hemorrhage, hepatic rupture, or infarction. 
Transfer to a tertiary care center is advocated. If the pregnant woman is at or 
beyond 34 weeks’ gestation or if there is any evidence of multiorgan dysfunction 
or severe complication, immediate induction of labor is recommended. 
Close monitoring of the mother should be continued after delivery also. 
Most laboratory values normalize in 48 hours after delivery of the fetus. 
Causes of perinatal mortality include abruptio placenta,asphyxia, and prematurity. 
Subsequent pregnancies in patients with HELLP syndrome carry a high risk of 
complications including recurrent HELLP.26,27 
 
ACUTE FATTY LIVER OF PREGNANCY 
AFLP occurs in 1 in 7000 to 16000 pregnancies.28,29 
Associated with microvesicular fatty infiltration of the liver, hepatic failure, and 
encephalopathy. It occurs commonly in the third trimester of pregnancy. 
Deficiencies of the enzymes of mitochondrial fatty acid beta oxidation (FAO) 
results in fatty infiltration of the liver. The most commonly enzyme deficiency is  
long-chain 2-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency. The defect is 
in the alpha subunit of the mitochondrial protein is associated with G1528C or 
E474Q mutations.30,31 Natarajan and colleagues 32 demonstrated that placental 
mitochondrial function is compromised in AFLP, which may lead to free radical 
production and accumulation of fatty acids in the placenta, resulting in maternal 
hepatocyte stress and mitochondrial dysfunction leading to acute liver failure. 
 40% to 50% of patients with AFLP are nulliparous with an increased incidence in 
twin pregnancies.33 Symptoms includes anorexia, nausea, emesis, malaise, 
fatigue, and headache. 
 On physical examination, the patient may have jaundice,hypertension, edema, and 
hepatic encephalopathy.  
Serum aminotransferase levels vary from 300 to 500 U/L. The total bilirubin 
concentration is usually less than 5 mg/dL. Other laboratory abnormalities include 
anemia, leukocytosis, normal or low platelet counts, coagulopathy with or without 
DIC, hypoalbuminemia, hypoglycemia,and acute kidney injury. 
Management includes hospitalization for stabilization of hypertension and DIC, 
seizure prophylaxis. Fetal monitoring followed by immediate delivery of the fetus 
or termination of the pregnancy along with intensive support. The aminotransferase 
levels and encephalopathy improve within 72 hours of delivery. Most recover in 1 
to 4 weeks post partum. 
Maternal mortality  is 3% to 12% and fetal mortality is 15% to 66%. The 
strong association of AFLP with LCHAD deficiency in the fetus suggests a 
necessity of neonatal testing for enzymatic defects of FAO. Women who are 
carriers of the LCHAD mutation have an increased risk of recurrence of AFLPin 
20%to 70%of pregnancies. 
 
Elevated level of serum bilirubin causes vasoconstrictive effect on the 
placental vessels and cardiotoxic effect resulting in fetal asphyxia and intrauterine 
death . Also elevated bilirubin produce cellular effect which stimulates uterine 
contractility and sensitizes  myometrium to oxytocin resulting in preterm labour. 
The fetomaternal complications of jaundice in pregnancy are not only due to 
jaundice alone but  largely due to the underlying causes of these  conditions. Thus 
the management depends on the underlying cause.  
Careful examination and vigilance is required to detect the early sign of 
hepatic dysfunction   and to differentiate  these from the physiological changes 
during  pregnancy.  Management of jaundice in pregnancy requires a combined 
effort of physician, gastroenterologist, obstetrician and on rare occasions, a liver 
transplant team.  
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MATERIALS AND METHODS 
Sixty five women with jaundice complicating pregnancy admitted and treated at 
Government Rajaji Hospital , Madurai from september 2011 to september 2012 
were studied. 
• A detailed history including patient’s age , socioeconomic status , booking , 
parity and details of menstrual history to arrive at the expected date of 
delivery  was obtained. 
• Patients were enquired in detail about their complaints and duration like 
nausea , vomiting , pruritus , anorexia , yellow coloured urine , pale stools , 
edema legs , bleeding tendency , joint pain , fever and others. 
• Past history of jaundice especially in previous pregnancy and  history of 
blood transfusion were elicited. 
•  systemic and obstetric examinations were carried out.  
• Investigations included liver function tests, serum billirubin, SGOT, SGPT, 
alkaline phosphatase, Viral markers, prothrombin time (PT), partial 
thromboplastin time (PTT), bleeding time (BT), clotting time (CT), platelet 
count and ultrasound abdomen were carried out as and when required.        
• HIV screeing was done in all patients. 
• Medical gastroenterologist opinion was obtained for all cases. 
• Labour was closely monitored. Jaundice perse was not an indication for 
cesarean section. Vaginal delivery with close monitoring was preferred and 
cesarean sections were done only for obstetric indication. After cross 
matching fresh blood was kept ready as alteration in coagulation profile was 
expected in jaundice complicating pregnancy. 
• Atonicity was managed with oxytocin drip , injection methergin and injection 
15 methyl PGF2α. 
• Patient were kept in the labour ward for close observation. Clotting time was 
repeated hourly if it was prolonged till it becomes normal. 
• Soon after delivery all babies were assessed by paediatrician. Alive or dead , 
sex , gestational age at birth , weight , apgar score and presence or absence of 
any congenital anomalies were looked for and noted. As per paediatrician 
opinion sick babies were admitted in preterm ward for intensive care.                                   
• Of the 65 women, 28 had viral hepatitis,8 AFLP, 6  HELLP , 3 cholestatic , 1 
hyperemesis ,1 haemolytic anaemia , 1 cirrhosis and 1 Gilberts. 
• The maternal outcome was noted in terms of the mode of termination of 
pregnancy, maternal complications and maternal mortality.The relation of 
maternal morbidity and mortality to the admission serum bilirubin level was 
analysed. 
• To identify the various etiologies and distribution of jaundice with reference to 
age , parity and trimesters. 
• Fetal outcome was assessed by perinatal morbidity and mortality 
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OBSERVATIONS AND RESULT 
 
The incidence of jaundice in India varies from 0.4 to 0.9/1000 deliveries. 
According to this study the incidence of jaundice is 2/1000 deliveries. Singh et al 1 
reported 1.03/1000 incidence while Kamalajayaram and Rama Devi 2 reported 
0.4/1000 incidence. Of the 65 women studied 58.5% were in 21 to 25 yrs of age 
(TABLE 1). Mean age is 23 yrs. About 47.7% were primi and 41.5% were second 
gravida ( TABLE 3 ). 70.7% were in third third trimester (TABLE 4). 
 
Etiologies for jaundice 
Of the 65 women, 28 had viral hepatitis (43.1%), 8 AFLP (12.3%),               
6  HELLP (9.2%), 3 cholestatic , 1 hyperemesis ,1 haemolytic anaemia , 1 cirrhosis 
and 1Gilberts.(table 10) Among the 28 viral hepatitis 60.7% was due to hepatitis E, 
hepatitis B 28.6% and hepatitis A 10.7. Two deaths were due to hepatitis E. Of the 
6 HELLP cases 3 expired (50% mortality) .  
 
Relation with serum bilirubin level  
Maternal mortality was directly related to the level of serum bilirubin as 
shown in (Table 9). 59 women were discharged in improved condition -  21 
undelivered and 38 delivered. Initial serum bilirubin level of  > 13 lead to 50% 
mortality. About 33.8% of women had an initial serum bilirubin level of about 5 – 
10 mg / dl. 
 
Pregnancy outcome 
Among the 65 women studied 43 women got delivered (66.2%). 22 women  
remained undelivered ( TABLE 4). Of these 22 women, one expired due to hepatic 
encephalopathy during 3rd trimester. Others improved and were discharged. Of the 
43 women delivered , 28 was vaginal delivery (65.1) , 1 outlet , 1 VBAC , 12 
LSCS (25.6%) and 1 spontaneous expulsion.   
4 cases of atonic PPH was observed. 3 were following vaginal delivery and one 
following outlet forceps delivery. 
One atonic PPH ended up in hysterectomy she subsequently deteriorated and 
expired due to hepatic encephalopathy. 
 
Maternal outcome 
28% developed hepatic encephalopathy, 28% ARF , 22% atonic PPH , 17% 
abruption and 5% DIC. (table 12) 
 
 
 
Cause of death 
In our study , six women expired . Hepatic encephalopathy  (66.7) was the 
cause in 4 out of 6 women who died. One women died of hepatorenal failure (16.7)  
and one due to acute cholangitis (16.7).(table 13) 
 
Fetal outcome 
0f the 43 women delivered , one was a twin delivery but only one baby 
survived. 86.4% born alive and 11..4 % were intrauterine death (table 8). 52.3 % 
were male babies and 47.4 %  were female babies (table 7). 68.2 % were preterm 
babies and 29.5 % were term babies (table 6). 52.3% of babies weighed < 2.5kg 
and 47.7 %  of babies weighed 2.5 – 3 kg. 
 
 
 
 
 
 
 
 
  
 
 
 
 
ANALYSIS 
 
 
 
 
 
 
 
 
 
 
 
 
 AGE DISTRIBUTION  (TABLE 1) 
 
AGE  PERCENTAGE 
<20 15 23 
21-25 38 58.5 
26-30 8 12.3 
31-35 2 3.07 
36-40 2 3.07 
 
Of the 65 women studied 58.5% were in 21 to 25 yrs of age . Mean age is 23 yrs. 
 
 
Mean 23.65 
Median 23.00 
Mode 24a 
Std. Deviation 3.797 
Variance 14.420 
Range 18 
 
  
 
 
 
                          AGE DISTRIBUTION 
 
 
 
Of the 65 women studied 58.5% were in 21 to 25 yrs of age
 
 
<20 21 - 25
15
 (CHART 1) 
 . Mean age is 23 yrs.
26 - 30 31 - 35 36 - 40
38
8
2
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 AGE 
  Frequenc
y Percent 
Valid 
Percent 
Cumulative 
Percent 
 18 4 6.2 6.2 6.2 
19 4 6.2 6.2 12.3 
20 6 9.2 9.2 21.5 
21 4 6.2 6.2 27.7 
22 6 9.2 9.2 36.9 
23 9 13.8 13.8 50.8 
24 10 15.4 15.4 66.2 
25 10 15.4 15.4 81.5 
26 1 1.5 1.5 83.1 
27 2 3.1 3.1 86.2 
28 4 6.2 6.2 92.3 
29 1 1.5 1.5 93.8 
31 1 1.5 1.5 95.4 
32 1 1.5 1.5 96.9 
36 2 3.1 3.1 100.0 
Total 65 100.0 100.0  
 
 
TRIMESTER DISTRIBUTION (TABLE 2) 
 
TRIMESTER TOTAL PERCENTAGE 
I 1 1.53 
II 18 27.7 
III 46 70.7 
 
The occurrence of jaundice was high during third trimester . 70.7% were in  third 
trimester. 
 
TRIMESTER DISTRIBUTION 
  
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
 I 1 1.5 1.5 1.5 
II 18 27.7 27.7 29.2 
III 46 70.8 70.8 100.0 
Total 65 100.0 100.0  
 
 
  
TRIMESTER  DISTRIBUTION(CHART 2) 
 
 
 
 
 
 
 
 
 
1%
28%
71%
I II III
PARITY DISTRIBUTION (TABLE 3) 
PARITY  PERCENTAGE 
PRIMI 31 47.7 
G2 27 41.5 
G3 5 7.7 
G4 1 1.53 
G5 1 1.53 
TOTAL 65  
 
Of the total 65 women studied ,  47.7% were primigravida  and 
41.5% were second gravida. 
 
 
 
 
 
 
  
 
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
      
G3 5 7.7 7.7 49.2 
G4 1 1.5 1.5 50.8 
G5 1 1.5 1.5 52.3 
PRIMI 31 47.7 47.7 100.0 
Total 65 100.0 100.0  
 
 
 
 
 
 
 PARITY DISTRIBUTION
Of the total 65 women studied , 
gravida. 
PRIMI G2
31
 
 (CHART 3) 
 
 47.7% were primigravida  and 41.5% were second 
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PREGNANCY OUTCOME 
DELIVERED
UNDELIVERED
TOTAL
 
43 out of 65 patients delivered (66.2%). 22 remained undelivered
one expired due to hepatic encephalopathy
and were discharged. 
PREGNANCY OUTCOME 
DELIVERED
(TABLE 4) 
 TOTAL PERCENTAGE
 43 66.2 
 22 33.8 
 65  
 during 3rd trimester. Others improved 
(CHART 4) 
UNDELIVERED
43
22
 
.  Of these 22, 
 
MODE OF DELIVERY (TABLE 5) 
MODE OF DELIVERY  PERCENTAGE 
LABOUR  NATURAL 28 65.1 
OUTLET 1 2.3 
VBAC 1 2.3 
CESAEREAN 12 25.6 
SPONTANEOUS 
EXPULSION 
1 2.3 
TOTAL 43  
 
Of the 43 delivered , 28 was labour natural (65.1) , 1 outlet , 1 VBAC , 12 
LSCS (25.6%) and 1 spontaneous expulsion.   
4 cases of atonic PPH was observed. 3 were following labour natural and one 
following outlet forceps delivery. 
 
 
 
MODE OF DELIVERY
3%
2%
28%
LN OUTLET
 
 
 (CHART 5) 
 
 
 
 
 
 
 
 
2%
VBAC CESAREAN SPONTANEOUS EXPULSION
65%
 MODE OF 
DELIVERY Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
 LABOUR 
NATURAL 
28 43.1 43.1 43.1 
LSCS 12 18.5 18.5 61.5 
OUTLET 
FORCEPS 
1 1.5 1.5 63.1 
SPONTANEOUS  
EXPULSION 
1 1.5 1.5 64.6 
UNDELIVERED 22 33.8 33.8 98.5 
VBAC 1 1.5 1.5 100.0 
TOTAL 65 100.0 100.0  
 
 
 
MATURITY OF BABY 
MATURITY OF 
BABY
PRETERM
TERM
ABORTUS
TOTAL
 
30 Babies out off 44 were premature
deaths. Remaining 28 admitted in preterm ward for intensive care. Inspite of 
intensive care 4 out of 28 babies expired.
PRETERM
30
MATURITY OF BABY  (CHART 6) 
(TABLE 6) 
 
TOTAL PERCENTAGE
 30 68.2 
 13 29.5 
 1 2.3 
 44  
.  2 out of this 30 babies were 
TERM ABORTUS
13
1
 
intrauterine 
 
 SEX OF THE BABY (TABLE 7) 
SEX OF THE 
BABY 
TOTAL PERCENTAGE 
MALE 23 52.3 
FEMALE 21 47.7 
TOTAL 44  
 
 
 
 
52%48%
SEX OF THE BABY  (CHART 7)
MALE FEMALE
FETAL OUTCOME (TABLE 8) 
FETAL 
OUTCOME 
TOTAL PERCENTAGE 
BORN ALIVE 38 86.4 
DEAD BORN 5 11.4 
ABORTUS 1 2.3 
 
0f the 43 delivered , one was a twin delivery but only one baby survived. 86.4% 
born alive and 11..4 % were intrauterine death . 52.3 % were male babies and    
47.4 %  were female babies. 68.2 % were preterm babies and 29.5 % were term 
babies. 
Of 12 babies expired, 6 babies were preterm and 6 babies were term. 2 out of 6 
preterm babies were dead born and 3 out of 6 term babies were dead born.  
 Inspite of intensive neonatal care 7 babies expired. 
 
 
 
 
FETAL OUTCOME 
 
 
(CHART 8) 
 
 
 
 
 
 
86%
12%
2%
BORN ALIVE DEAD BORN ABORTUS
 
LEVEL OF INITIAL BILIRUBIN (TABLE 9) 
INITIAL  
BILIRUBIN 
TOTAL PERCENTAGE 
<5 31 47.7 
5-10 22 33.8 
10-15 10 15.4 
>15 2 3.1 
 
Maternal mortality  and morbidity was directly related to the initial level of 
serum bilirubin . Initial serum bilirubin level of  > 13 lead to 50% mortality. About 
33.8% of women had an initial serum bilirubin level of about 5 – 10 mg / dl. 
Keeping the initial bilirubin level at admission as 10 mg/dl , the maternal 
outcome was poor and high mortality rate was seen when the bilirubin level 
exceeds 10 mg/dl. It is statistically significant. 
 
 
 
LEVEL OF INITIAL BILIRUBIN 
When the initial serum bilirubin level is  > 13the mortality rate 
was upto 50%. 
 
 Bilirubin  
level Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Deaths 
 <13 57 87.7 87.7 87.7 3 
>13 8 12.3 12.3 100.0 3 
Total 65 100.0 100.0   
 
 Bilirubin 
level Frequency Percent Valid Percent 
Cumulative 
Percent 
 <10 55 84.6 84.6 84.6 
>10 10 15.4 15.4 100.0 
Total 65 100.0 100.0  
 INITIAL BILIRUBIN LEVEL
 
 
<5
31
 
 (CHART 9 )
 
 
 
 
 
 
 
 
 
5 TO 10 10 TO 15 >15
22
10
 
 
2
STATISTICAL SIGNIFICANCE OF INITIAL 
BILIRUBIN LEVEL 
 
(using chi square test) 
 
BILIUBIN 
LEVEL 
 
EXPIRED 
 
 
RECOVERED 
 
TOTAL 
A (<10) 3 52 55 
B (>10) 3 7 10 
TOTAL 6 59 65 
 0.092 0.907  
 
 
 
 
 INITIAL 
BILIRUBIN 
LEVE L 
 
EXPIRED 
 
RECOVERED 
 
TOTAL 
 
< 10 
O =  3 
E = 5.06 
     2.06 
0 = 52 
E = 49.9 
             2.1 
 
55 
 
> 10 
O =  3 
E = 0.92 
     2.08 
0 = 7 
E = 9.07 
     2.07 
 
10 
TOTAL 6 59 65 
 
 
χ
 2
= 6.104 
 
From the probability table of Χ 2, probability (P) value is found 
to be around 0.01. 
Hence the difference in the recovery pattern between the two 
groups is statistically significant. 
HENCE THE INITIAL BILIRUBIN LEVEL AT ADMISSION 
> 10 IS ASSOCIATED WITH POOR MATERNAL 
OUTCOME AND HIGH MATERNAL MORTALITY. 
 
 
 
 
 
 
 
 
ETIOLOGY OF JAUNDICE (TABLE 10) 
ETIOLOGY OF JAUNDICE TOTAL PERCENTAGE 
VIRAL 28 43.1 
AFLP 8 12.3 
HELLP 6 9.2 
OBSTRUCTIVE 3 4.62 
HYPEREMESIS 1 1.5 
HAEMOLYTIC ANAEMIA 1 1.5 
CIRRHOSIS 1 1.5 
GIBERTS 1 1.5 
UNKNOWN 16  
 
Of the 65 women studied , 28 had viral hepatitis (43.1%), 8 AFLP (12.3%), 
6  HELLP (9.2%), 3 cholestatic , 1 hyperemesis ,1 haemolytic anaemia , 1 cirrhosis 
and 1Gilberts syndrome.   
 
 
  
ETIOLOGY 
FREQUEN
CY 
PERCEN
T 
VALID 
PERCENT 
CUMULATI
VE 
PERCENT 
 AFLP 8 12.3 12.3 12.3 
CHOLESTATIC 3 4.6 4.6 16.9 
CIRRHOSIS WITH 
PORTAL 
HYPERTENSENSION 
1 1.5 1.5 18.5 
GILBERT 1 1.5 1.5 20.0 
HAEMOLYTIC 1 1.5 1.5 21.5 
HELLP 6 9.2 9.2 30.8 
HEPATITIS A 3 4.6 4.6 35.4 
HEPATITIS B 8 12.3 12.3 47.7 
HEPATITIS E 17 26.2 26.2 73.8 
HYPEREMESIS 1 1.5 1.5 75.4 
UNKNOWN 16 24.6 24.6 100.0 
TOTAL 65 100.0 100.0  
 
 
 
 ETIOLOGY OF JAUNDICE
12%
1%
2%
2%
25%
VIRAL
OBSTRUCTIVE
AFLP
CIRRHOSIS
UNKNOWN
 (CHART 10)
 
9%5%
1%
HELLP
HYPEREMESIS
HEMOLYTIC ANAEMIA
GILBERTS
 
 
43%
 TYPES OF VIRAL ETIOLOGIES  (TABLE 11) 
 
VIRAL TOTAL PERCENTAGE 
E 17 60.7 
B 8 28.6 
A 3 10.7 
 
Of the 65 women studied , 28 had viral hepatitis (43.1%) . Among the 28 viral 
hepatitis 60.7% was due to hepatitis E , hepatitis B 28.6% and hepatitis A 10.7.  
Out of 12 fetal deaths , 5 babies  were born  to women with viral hepatitis. Of these 
5 , 4 were due to viral hepatitis E. 
Of the 28 women with viral hepatitis two women expired due to hepatic 
encephalopathy. And both were hepatitis E virus. 
 
 
 
TYPE OF VIRAL ETIOLOGIES
HEPATITIS E
HEPATITIS B
HEPATITIS A
 
 (CHART 11)
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MATERNAL COMPLICATIONS  (TABLE 12) 
 
MATERNAL 
COMPLICATIONS 
  
PERCENTAGE 
HEPATIC 
ENCEPHALOPATHY 
 
5 
 
28 
ARF 5 28 
ATONIC PPH 4 22 
ABRUPTION 3 17 
DIC 1 5 
 
 
28% developed hepatic encephalopathy, 28% ARF , 22% atonic PPH , 17% 
abruption and 5% DIC. 
 
 
 
 
MATERNAL COMPLICATIONS (CHART 12 )
5%
HEPATIC ENCEPHALOPATHY
 
 
 
 
 
 
 
 
28%
22%17%
28%
ATONIC PPH ABRUPTION DIC
 
 
ARF
CAUSE OF DEATH  (TABLE 13) 
 
CAUSE OF DEATH  PERCENTAGE 
HEPATIC 
ENCEPHALOPATHY 
4 66.7 
HEPATORENAL 
SYNDROME 
1 16.7 
CHOLANGITIS 1 16.7 
 
Six women expired. Hepatic encephalopathy  (66.7 %) was the cause in 4 out of 6 
women who died. 0ne women died of hepatorenal failure (16.7 %)  and one due to 
acute cholangitis (16.7 %) 
 
 
 
 
 
CAUSE OF DEATH
HEPATIC  ENCEPHALOPATHY
4
 
  (TABLE 13) 
 
 
 
HEPATORENAL SYNDROME CHOLANGITIS
1
 
1
 BIRTH WEIGHT (TABLE 13) 
 
BIRTH 
WEIGHT 
 PERCENTAGE 
<2.5 23 52.3 
2.5 – 3.5 21 47.7 
>3.5 -  
 
Maximum weight among the 44 babies was 3.5 kg 
 
 
 
 
 
 
 
  
BIRTH WEIGHT
 
48%
<2.5
 (CHART 13) 
0%
2.5 – 3.5 >3.5
 
52%
 BLOOD TRANSFUSIONS
TRANSFUSIONS
<5 
5-10 
10-15 
15-20 
>20 
 
 
<5
5 TO 10
10 TO 15
15 TO 20
> 20 2
 (TABLE 14) 
  
18 
10 
3 
 
2 
10
3
BLOOD TRANSFUSIONS
 
18
PERINATAL DEATHS (TABLE 15) 
 
ETIOLOGY 
 
PRETERM / 
TERM 
 
MODE OF 
DELIVERY 
 
SEX OF 
THE BABY 
SERUM 
BILIRUB
IN 
 
VIRAL 5 
(41.7 %) 
 
PRETERM -2 
TERM -3 (2 
OUT 3 WAS 
DEAD BORN) 
 
LABOUR 
NATURAL -4 
OUTLET 1 
 
MALE - 2 
FEMALE -3 
<5 - 1 
5 to10 -2 
10 to15 -2 
 
 
HELLP 3 
(25 %) 
 
PRETERM - 3 
(2 OUT 3 WAS 
DEAD BORN) 
 
LABOUR 
NATURAL – 2 
LSCS - 1 
 
MALE -3 
 
 
5 to10- 1 
10 to15 -1 
>15 -1 
 
CHOLESTASIS 
1 (8.3 %) 
 
PRETERM  - 1 
 
 
LSCS - 1 
 
MALE - 1 
 
 
5 to10- 1 
 
 
AFLP 2 (16.7 %) 
 
TERM -2 
LABOUR 
NATURAL – 1 
LSCS - 1 
 
MALE -1 
FEMALE -1 
 
<5 -1 
10 to15 -1 
 UNKNOWN  
1 (8.3 %) 
 
TERM  - 1 
(DEAD BORN) 
 
LSCS 
 
MALE - 1 
 
10 to15-1 
 
 
Among the 12 babies expired 6 babies were term and 6 babies were preterm.  2 out 
of 6 preterm babies were dead born and 3 out of 6 term babies were dead born.  
Out of 12 fetal deaths , 5 babies  were born  to women with viral hepatitis. Of these 
5 , 4 were due to viral hepatitis E. 
30  babies admitted for intensive care. Inspite of intensive neonatal care 7 babies 
expired. 
5 deaths have occurred when the maternal initial bilirubin was in the range of 10 -
15 mg/dl. 
 
 
 
 
 
 
 COMPARISON WITH REPORTED MATERNAL DEATHS DUE TO 
JAUNDICE 
 
 
Authors 
 
 
Year 
Percentage of deaths due to 
jaundice amongst total maternal deaths 
 
Kamalajayaram and Rama Devi  
 
1988 
 
 
12.4 
 
Rao and Rudra  
 
2001 
 
15.8 
 
Roychowdhary et al  
 
1990 
 
13.37 
 
Bera and Sengupta  
 
1992 
 
19.9 
 
Sapre and Joshi  
 
1999 
 
04.99 
 
Trivedi et al  
 
2003 
 
29.3 
 
According to this study 
 
2012 
 
7.9 
 
  
 
 
 
 
 
 
 
DISCUSSION 
 
 
 
 
 
 
 
 
DISCUSSION 
The incidence of jaundice in India varies from 0.4 to 0.9/1000 deliveries. 
According to this study incidence is 2/1OOO  deliveries. Singh et al 34 reported 
1.03/1000 incidence while Kamalajayaram and Rama Devi 35  reported 0.4/1000 
incidence. Jaundice occurring in pregnancy can be due to acute yellow atrophy of 
liver due to infective hepatitis of A, B, C, D or E type. Cholestatic jaundice is also 
common during pregnancy, in which serum bilirubin levels of up to 6 mg% are 
seen with either minimal or no increase in serum enzyme levels. It is associated 
with prematurity in 19.5% and a perinatal mortality rate of 30%. 
 
HELLP syndrome is present in 3-10% of preeclamsia. It is associated with weight 
gain and edema in 60%, maternal mortality of 20%, DIC in 4-38%, neonatal 
mortality rate of 31%, and rupture and hematoma of the liver in 2% 36. 
 
Acute fatty liver during pregnancy usually occurs in the 3rd trimester. Preeclampsia 
is associated in 50-100% of cases. There is moderately increased liver enzyme 
level of <1000 IU/mL, bilirubin level of 1-10mg% and hypoglycemia. The 
maternal mortality is 18% while preterm labor is increased and the perinatal 
mortality is 23% 36.  
Jaundice in pregnancy is associated with high maternal and perintal mortality   
rates.High perinatal mortality rate of 45.45% was observed by Singh et al 34.  
According to this study percentage of fetal deaths due to jaundice amongst 
total perinatal deaths is 2%. Maternal mortality  reported by various authors. 
Kamalajayaram and Rama Devi 35 reported 33.3% maternal mortality and Singh et 
al 34 reported 10%.   
According to this study percentage of maternal  deaths due to jaundice 
amongst total maternal deaths is 7.9 %  which is nearly comparable with the study 
conducted by Sapre and Joshi  .  
Hepatorenal failure, encephalopathy.DIC and postpartum hemorrhage were 
responsible for the deaths. According to this study hepatic encephalopathy  (66.7 
%) was the cause in 4 out of 6 women who died , one women died of hepatorenal 
failure (16.7 %)  and one due to acute cholangitis (16.7 %) 
Various studies also report jaundice as one of the major indirect cause of maternal 
death, responsible for 5 to 30% of all maternal deaths 35,37-41 . Maternal deaths were 
directly proportional to the level of the serum bilirubin. Trivedi et al 41 also 
observed the same. According to this study the initial bilirubin level at admission  
> 10 is associated with poor maternal outcome and high maternal mortality. 
 
 
 
  
 
 
 
 
 
CONCLUSION 
 
 
 
 
 
 
 
 
 
 
  
CONCLUSION 
Jaundice in pregnancy is associated with high maternal and perintal 
mortality rates. 
Viral hepatitis is the leading cause of jaundice according to our study with 
hepatitis E being the predominant virus. Hepatic encephalopathy and renal failure 
are the two important maternal complications. Hepatic encephalopathy is the  
common cause of death according to our study. 
According to this study the initial bilirubin level at admission  > 10 is 
associated with poor maternal outcome and high maternal mortality. 
The factors responsible for a high maternal mortality in our country may be 
poor nutrition and hygiene, prevalence of anemia, delay in seeking medical advice, 
and delay in referral to the hospital. Many of the patients when brought to the 
tertiary health care system are already in moribund condition and often, do not 
respond to treatment. 
 
 
 
 
  
 
CIRRHOSIS WITH PORTAL HYPERTENSENSION 
 
 
  
Patient recovered from hepatic encephalopathy 
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PROFORMA 
 
 
 
 
 
 
 
 
 
MATERNAL AND FETAL OUTCOME IN JAUNDICE 
COMPLICATING PREGNANCY 
 
 
NAME:                                                                         AGE:                                                       IPNO: 
D.O.A: 
D.O.DELIVERY: 
D.O.DISCHARGE: 
PARITY: 
L.M.P:                                                                             E.D.D: 
COMPLAINTS: 
 
 
HOPI: 
 
 
 
PAST H/O: 
 
MENSTRUAL H/O:  
 
MARITAL H/O: 
 
OBSTETRICS H/O: 
 
ON EXAMINATION:  CONSCIOUS/ORIENTED -                                                          ANAEMIC 
TEMPERATURE-                                         PEDAL EDEMA-                                               ICTERIC – MILD/SEVERE 
PR-                                         BP-                                CVS-                                    RS- 
P/A- 
 
P/V- 
 
 
 
INVESTIGATIONS: 
HB% - 
URINE ALBUMIN 
            SUGAR  
            DEPOSIT 
            BS/BP 
BLOOD   SUGAR 
                UREA 
                S.CREATININE 
LFT        T.BILIRUBIN 
                  DIRECT 
             INDIRECT 
              SGOT 
              SGPT 
              ALP 
              LDH 
PLATLET COUNT 
CLOTTING TIME 
BLEEDING TIME 
PROTHROMBIN TIME  
ACTIVATED PARTIAL THROMBOPLASTIN TIME 
VIRAL MARKERS: 
 
 
ULTRASOUND: 
 
 
MANAGEMENT: 
LIVER SUPPORTIVES 
BLOOD AND BLOOD PRODUCTS TRANSFUSION: 
 
ICU CARE: 
 
MATERNAL OUTCOME: 
 
MODE OF DELIVERY: 
PERINATAL OUTCOME: 
SEX:                                          TERM/PRETERM:                                                 ALIVE/DEAD BORN/STILL BIRTH 
APGAR 1MIN                         5 MIN                                                                      CONGENITAL ANOMALIES: 
 
 
  
 
 
 
 
 
MASTER CHART 
 
 
 
 
 
 
 
 
 
 
S.N
O 
NAME AGE PARITY TRIMESTER INITIAL 
BILIRUBIN 
ETIOLOGY MATERNAL OUTCOME PERINATAL OUTCOME 
       TRANSFUSIO
NS 
MODE OF DELIVERY ICU 
CARE 
COMPLICATION
S 
TERM/ 
PRETERM 
APGAR SEX B.WT IN 
KG 
1. MAHESWARI 21 PRIMI III 1 VIRAL 
(HEV) 
2 FFP LN WITH EPI - - PRETERM 2/10 
5/10 
FCH 2.2  
2. INDUJA 25 PRIMI III 1 VIRAL 
(HBV) 
- LN WITH EPI - - PRETERM 5/10 
7/10 
FCH 2.3  
3. SHANTHI 28 G4P2L2
A2 
III 1 VIRAL 
(HBV) 
- LN WITH LP 1 - - TERM  5/10 
6/10 
FCH 2.7 
4. PONNUTHAI 21 PRIMI III 5.4 VIRAL 
(HEV) 
5 FFP OUTLET FORCEPS 
WITH EPI 
- ATONIC PPH 
TENDERNESS 
ON BOTH LL 
TERM 
SEVERLY 
ASPHYXIAT
ES 
0/10(BAB
Y COULD 
NOT BE 
REVIVED) 
MCH 3.5 
5. KARTHIGA 32 G2P1L1 III 9.5 VIRAL 
(HBV) 
- REPEAT LSCS - - TERM 5/10 
6/10 
FCH 2.9 
6. MUTHUMARI 23 PRIMI III 8 VIRAL 
(HEV) 
2 FFP , I WB UNDELIVERED - EXPIRED  
(HEPATIC 
ENCEPHALOPA
THY) 
- - - - 
7. SYED ALI 24 G2P1L1 II 5.1 CHOLEST
ATIC 
2 PC UNDELIVERED - - - - - - 
8. ASHINA 
BANU 
29 G3P2L2 III 3 VIRAL 
 (HEV) 
1 FFP LNWITH EPI - - TERM 6/10 
8/10 
MCH 3.3 
9. SUMATHI 24 G2P1L0 III 15 VIRAL 
 (HAV) 
I PC LN WITH EPI - - TERM 6/10 
7/10 
MCH 3 
10. PETCHIYAMM
AL 
36 G2P1L0 II 3.5 CIRRHOSI
S WITH 
PORTAL 
HYPERTE
NSENSIO
N 
5 PC 
7 FFP 
1 WB 
UNDELIVERED - - - - - - 
11. ALAGULAKSG
MI 
24 PRIMI III 10.1 AFLP I WB 6 FFP LSCS (PRIMI / CPD / 
FETAL DISTRESS) 
- - TERM 2/10 
5/10 
MCH 2.8 
12. MUTHUMARI 20 G2P1L0 III 1 - - LN WITH EPI - - TERM 5/10 
7/10 
MCH 2.1 
13. MAHALAKSH
MI 
18 PRIMI III 5.5 VIRAL  
(HAV) 
5 FFP LN WITH EPI - - TERM IUD FCH 1.6 
14. VIJAYALAKSH
MI 
27 G5P1L1
A5 
II 12.5 VIRAL 
 (HAV) 
- LN - K/C/O ARNOLD 
CHIARI MALF 
TYPE1/ 
SYRINGOMYELI
A 
TERM  4/10 
5/10 
MCH 2.3 
15. AMUTHESWA
RI 
22 PRIMI III 8 AFLP - LN WITH EPI - - TERM 6/10 
7/10 
FCH 2.2 
16. MUTHULAKS
HMI 
24 PRIMI III 3 - - UNDELIVERED - - - - - - 
17. ANGELMARY 25 G3P1L1
A1 
III 0.9 - - UNDELIVERED - - - - - - 
18. SELVI 24 G2P1L1 III 8.9 AFLP 1 WB 1 
PLATLET 
LN WITH EPI - - TERM  FCH 2.6 
19. DEEPA 22 G2P1L1 
(PREV 
LSCS) 
II 9.5 - - UNDELIVERED - - - - - - 
20. KARPAGAVAL
I 
24 G2P1L1 
(PREV 
LSCS) 
II 9.1 - - UNDELIVERED - - - - - - 
21. RAJESWARI 18 PRIMI III 16.6 - 2 FFP LN WITH EPI - ELEVATED 
RENAL 
PARAMETERS 
TERM  MCH 2.6 
22. PREMA 23 G2P1L1 III 7.8 - - LSCS - GR I 
ABRUPTION 
   2.3 
23. TAMIL 
ELAKYA 
25 PRIMI III 1 VIRAL 
 (HEV) 
- LN WITH EPI - - TERM  FCH 3 
24. NAGAJOTHI 19 PRIMI II 0.8 VIRAL 
 (HEV) 
- UNDELIVERED - - - - - - 
25. NAGALAKSH
MI 
23 G2P1L1 III 0.8 VIRAL 
 (HEV) 
2 FFP LN WITH EPI - - TERM  MCH 3.5 
26. PUSPAVALLI 28 G2P1L1 II 5 VIRAL 
 (HEV) 
- UNDELIVERED - - - - - - 
27. LAKSHMI 22 PRIMI  II 7 AFLP - UNDELIVERED - - - - - - 
28. UMA 
MAHESWARI 
26 PRIMI II 2.5 VIRAL 
 (HBV) 
 UNDELIVERED - - - - - - 
29. SARAMMAL 23 G2P1L1 II 2.5 - - UNDELIVERED - - - - - - 
30. VEERALAKSH
MI 
24 G2P1L1 
(PREV 
LSCS) 
III 3 - - VBAC - - TERM 6/10 
8/10 
FCH 2.3 
31. MEERAJ 
BANU 
22 PRIMI III 3 VIRAL 
 (HBV) 
- LN WITH EPI - - PRETERM  FCH 2.1 
32. KALESWARI 25 G2P1L1 II 2.5 - - UNDELIVERED - - - - - - 
33. BHAVANI 25 G2P1L1 II 3 VIRAL 
 (HEV) 
- UNDELIVERED - - - - - - 
34. JEGADAMMA
L 
22 PRIMI II 1.9 - - UNDELIVERED - - - - - - 
35. MUTHULAKS 21 PRIMI II 7 VIRAL - UNDELIVERED - - - - - - 
HMI (HEV) 
36. DHANALAKSH
MI 
23 PRIMI III 4.5 HELLP 3 WB , 3 FFP 
,1 PLATLET 
LSCS Y EXPIRED ON 7
TH
 
POD- HEPATIC 
ENCEPHALOPA
THY 
TERM 8/10 
9/10 
FCH 2.6 
37. KAVITHA 28 PRIMI III 6.5 - 2 PC , 2 FFP LN /LP 1 - ?HAEMOLYTIC 
ANAEMIA, 
ELEVATED 
RENAL 
PARAMETER, 
MR GR I   
PRETERM 5/10 
6/10 
FCH 1.8 
38. MAHALAKSH
MI 
25 G2P1L1
/ PREV 
LSCS 
III 12.5 - 3 PC LSCS IRCU RUPTURE 
UTERUS 
TERM IUD MCH  2.7 
39. KARTHIGA 
DEVI 
18 PRIMI  III 3 HELLP 7 FFP 1 PC 4 
HUMAN 
ALBUMIN 
LSCS MICU GDM TERM 5/10 
7/10 
FCH 2.9 
40. LAKSHMI 
PRIYA 
22 G2P1L1 I 3 HG - UNDELIVERED - - - - - - 
41. PANDIMEENA 19 PRIMI III 2 VIRAL   
(HBV) 
3 PC LN / EPI - - TERM 4/10 
7/10 
MCH  2.25 
42. CHINNAPON
NU 
20 PRIMI II 3.5 AFLP 1 FFP 1 
PLATLET 
UNDELIVERED - - - - - - 
43. MEENA 19 PRIMI III 10.2 VIRAL 
(HEV) 
1WB 3 FFP 1 
PLATLET 
LN/EPI - - TERM 6/10 
7/10 
FCH 2.6 
44. SUMATHI 23 G2P1L1 III 1 - 1 WB  REPEAT LSCS - - TERM 6/10 
7/10 
MCH  2.5 
45. NAGAJOTHI 27 G2P1L1
/ IUD 
III 19.1 HELLP 
 
 
 
7 FFP 2 WB 4 
PLATLETS 
REPEAT LSCS IMCU ? 
HEPATORENAL 
SYND – I HD 
DONE 
EXPIRED ON 
PRETERM IUD MCH  1.8 KG 
46. THULASIMAN
I 
23 G2P1L1 III 1.3 VIRAL 
(HBV) 
- LN/EPI - - TERM 6/10 
7/10 
FCH 2.3 
47. CHELLAMMA
L 
18 PRIMI III 3 - - LN/EPI - - TERM 5/10 
6/10 
MCH 2.6 
48. MUTHUKANN
U 
25 G2P1L1
/ TWINS 
II 2.6 - - UNDELIVERED - - - - - - 
49. MAHALAKSH
MI 
20 PRIMI II 2.5 HELLP - SPONT. EXP - - ABORTION 3/10 
4/10 
FCH 900 
50. BANUPRIYA 21 PRIMI III 5 HELLP  
1 PC 2 FFP 
LN 
 
- - PRETERM IUD MCH 1.5 
51. SEETHALAKS
HMI 
25 G2P1L1 III 3.5 AFLP 2 WB, 1 PC, 1 
FFP, 1 PLT 
REPEAT LSCS - - TERM 7/10 
8/10 
FCH 2.8 
52. PARAMESWA
RI 
28 G3P2L2 
TWINS 
III 13.5 VIRAL  
(HEV) 
6 PC , 1O FFP, 
4 WB , 2 
PLATLET 
LN/EPI IRCU ATONIC PPH  
HYSTERECTOM
Y DONE 
EXPIRED – 
HEPATIC 
ENCEPHALOPA
THY 
PRETERM 1-5/10 
7/10 
2-1/10 
3/10 
BOTH  
MCH 
I – 1.86 
II – 2.2 
53. CHANDRA 36 PRIMI III 15 GILBERTS 5 FFP 1 WB LSCS MICU - PRETERM 6/10 
7/10 
MCH 2 
54. NAGALAKSH
MI 
25 G3P1L1
A1 
II 10.6 VIRAL 
 (HEV) 
- UNDELIVERED - - - - - - 
55. SHANTHI 23 PRIMI III 8 VIRAL 
 (HBV) 
- LN/EPI - - LATE 
PRETERM 
6/10 
7/10 
MCH 2 
56. MANIMALA 25 G2P1L1 
PREV 
LSCS 
III 8 VIRAL  
(HEV) 
- UNDELIVERED - - - - - - 
57. SABARNISHA 20 PRIMI III 9 VIRAL 
 (HEV) 
5 FFP 1 
PLATLET 1 
WB 
LN/EPI - ATONIC PPH  TERM 6/10 
7/10 
MCH 2.75 
58. KARTHIGA 23 G2P1L1 III 13 HELLP 18 WB 6 FFP 
4 PLATLET 
LN IMCU ATONIC 
PPH/DIC/ARF 
EXPIRED DUE 
TO HEPATIC 
ENCE 
 
PRETERM 
2/10 
5/10 
MCH 1.9 
59. KALAIVANI 24 G2P1L1 III 1.6 AFLP 2 FFP  LN/EPI - - TERM  RESUS 
FAILURE 
FCH 3.2 
60. THILAGAVAT
HY 
20 PRIMI III 9.5 VIRAL 
 (HEV) 
1WB 6 FFP LN/EPI IMCU HEPATIC 
ENCEPHALOPA
THY 
IUD - FCH 2 
61. AMUTHA 24 G2P1L1 III 2 HAEMOLY
TIC  
2 FFP REPEAT LSCS MICU PIGMENTED 
NEPHROPATHY 
TERM 5/10 
7/10 
MCH 2.7 
62. CHITHRADEVI 24 G3P2L2 III 9 VIRAL   
(HEV) 
1 WB 2 FFP LN - - PRETERM 5/10 
6/10 
MCH 1.75 
63. MEENATCHI 19 PRIMI III 12 AFLP 1 WB 2 FFP LN/EPI - - TERM 5/10 
6/10 
FCH 3 
64. AMUTHA 20 PRIMI III 7.2 CHOLEST
ATIC 
I FFP UNDELIVERED - - - - - - 
65. KAMATCHI 31 G2P1L1 III 8 CHOLEST
ATIC 
2 FFP REPEAT LSCS IRCU EXPIRED 
(ACUTE 
CHO;ANGITIS) 
PRETERM 3/10 
4/10 
MCH 1.5 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
